Fred Aslan, President and CEO at Artiva Biotherapeutics, Inc. (ARTV), sold 3,187 shares at $6.00 ($19K) on 2025-12-15, disclosed to the SEC on 2025-12-15.
Scheduled sale ($19k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ARTV | SELL | 2026-05-19 | $244K | — | Filing → |
| ARTV | SELL | 2025-11-17 | $22K | — | Filing → |
| ARTV | SELL | 2025-10-17 | $153K | — | Filing → |